Fate Therapeutics, Inc. (FATE)
- Previous Close
3.7000 - Open
3.7700 - Bid 3.8700 x 100
- Ask 3.9500 x 200
- Day's Range
3.7100 - 4.0600 - 52 Week Range
1.6300 - 8.8300 - Volume
3,786,921 - Avg. Volume
2,582,140 - Market Cap (intraday)
443.886M - Beta (5Y Monthly) 1.80
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6400 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.80
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
www.fatetherapeutics.comRecent News: FATE
Performance Overview: FATE
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FATE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FATE
Valuation Measures
Market Cap
421.12M
Enterprise Value
209.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.73
Price/Book (mrq)
1.14
Enterprise Value/Revenue
3.30
Enterprise Value/EBITDA
-1.22
Financial Highlights
Profitability and Income Statement
Profit Margin
-253.30%
Return on Assets (ttm)
-18.32%
Return on Equity (ttm)
-37.76%
Revenue (ttm)
63.53M
Net Income Avi to Common (ttm)
-160.93M
Diluted EPS (ttm)
-1.6400
Balance Sheet and Cash Flow
Total Cash (mrq)
315.18M
Total Debt/Equity (mrq)
28.10%
Levered Free Cash Flow (ttm)
-74.25M
Research Analysis: FATE
Company Insights: FATE
FATE does not have Company Insights